Carbon Biosciences is a biotech company developing a parvovirus-based vector platform. It is designed to deliver gene therapy payloads with high tissue specificity and minimal neutralizing immunity. The company researches a candidate gene CGT-001 that is able to target upper airway tissue in cystic fibrosis models.